Sixteen weeks of efruxifermin treatment (A Study of Efruxifermin in Subjects with Histologically Confirmed Nonalcoholic Steatohepatitis (NASH), NCT03976401, phase 2) provided a significant reduction in the hepatic fat fraction (HFF), serum ALT levels and improvement in NAS (≥2 scores) without worsening of fibrosis. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.